Dr. Kropotova is a biopharmaceutical executive with 20+ years of global R&D experience in all phases of global clinical development, translational medicine, and medical affairs. Currently, she is Executive Vice President & Chief Medical Officer at SAb Biotherapeutics, leading the strategy, direction, and execution of the company’s portfolio of innovative polyclonal antibody assets. Prior to joining SAb Biotherapeutics, Dr. Kropotova was Therapeutic Area Head of Global Specialty R&D at Teva Pharmaceuticals, leading innovative drug development across a broad portfolio of immunology and immuno-oncology assets spanning from pre-IND to BLA/NDA filing of biologics and complex drug-device combination products. Dr. Kropotova also served in various roles at Sanofi, including Vice President, Strategy & Strategic Planning Head, North American Medical Affairs; Associate Vice President and subsequently Vice President, Immuno-Inflammation, Global R&D Clinical Development; and Senior Medical Director, Respiratory, Allergy & Anti-Infectives. She also served in various roles at Wyeth and Pfizer. Dr. Kropotova received her MBA from Ohio University Graduate School of Business, Athens, Ohio; and her M.D. in Internal Medicine from the Vladivostok State Medical University, Vladivostok, Russia.
Team